Posted by Michael Wonder on 25 Aug 2021
FDA accelerates review of Novartis STAMP inhibitor asciminib (ABL001) for patients with chronic myeloid leukaemia
25 August 2021 - Novartis today announced that the US FDA accepted and granted priority review to the company’s new drug application for asciminib (ABL001) in chronic myeloid leukaemia, following its submission under the FDA's Real-Time Oncology Review program.
Novartis has previously received orphan drug, fast track and two breakthrough therapy designations for asciminib.
